Celgene Wants Barr's Antitrust Claims Put On Hold

Law360, New York (November 5, 2007, 12:00 AM EST) -- Celgene Corp. is asking a New Jersey court to put the antitrust and unfair competition counterclaims Barr Laboratories Inc. lodged in response to Celgene's patent infringement complaint over the cancer drug Thalomid on the back burner, arguing that letting the counterclaims go forward now would waste the court's time.

On Friday, Celgene filed its motion to bifurcate and stay discovery of Barr's antitrust and unfair competition counterclaims, which Barr filed on Oct. 10 when it answered Celgene's amended complaint, which asserted eight Thalomid patents against Barr....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.